GSK (GSK) Expected to Announce Earnings on Wednesday

Key Points

• GSK is expected to report Q3 2026 results on October 28, with analysts forecasting earnings of $1.33 per share and revenue of $11.74 billion. The company’s FY 2026 EPS guidance is 4.900–5.000.
• In its latest quarter, GSK beat expectations with $1.36 EPS and $11.14 billion in revenue, up 5.3% year over year. The company also raised its quarterly dividend to $0.4515, implying an annualized yield of about 3.6%.
• GSK’s pipeline and recent regulatory wins are supporting its growth outlook, including expanded approval for Jemperli, approval of a hepatitis B drug and encouraging early data for lung cancer therapy risvutatug rezetecan. Despite this potential, analysts maintain a consensus “Hold” rating with a $55.33 average price target.

GSK (NYSE:GSK - Get Free Report) will likely be posting its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to announce earnings of $1.33 per share and revenue of $11.74 billion for the quarter. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Parties may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.27 by $0.09. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.02 billion. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.47 earnings per share. On average, analysts expect GSK to post $4.78 EPS for the current fiscal year and $5.00 EPS for the next fiscal year.

GSK Stock Up 2.3%

GSK stock opened at $50.60 on Wednesday. The business has a 50-day moving average of $49.55 and a 200-day moving average of $51.54. GSK has a fifty-two week low of $42.85 and a fifty-two week high of $61.69. The stock has a market capitalization of $102.34 billion, a P/E ratio of 15.82, a P/E/G ratio of 2.23 and a beta of 0.33. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 8th. Investors of record on Friday, August 14th were paid a $0.4515 dividend. This is a boost from GSK's previous quarterly dividend of $0.44. The ex-dividend date was Friday, August 14th. This represents a $1.81 dividend on an annualized basis and a yield of 3.6%. GSK's dividend payout ratio (DPR) is currently 55.31%.

Analyst Upgrades and Downgrades

A number of research firms have commented on GSK. HSBC restated a "hold" rating on shares of GSK in a research note on Thursday, September 10th. JPMorgan Chase & Co. restated a "sell" rating on shares of GSK in a report on Thursday, October 1st. The Goldman Sachs Group reaffirmed a "neutral" rating on shares of GSK in a research report on Monday, June 29th. Citigroup initiated coverage on GSK in a research note on Friday, July 24th. They issued a "neutral" rating for the company. Finally, Morgan Stanley reaffirmed an "underweight" rating on shares of GSK in a report on Tuesday, August 25th. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $55.33.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA granted accelerated approval to GSK’s Jemperli (dostarlimab) for adults with locally advanced rectal cancer characterized by MSI-H or dMMR biomarkers. The approval expands Jemperli’s commercial opportunity and strengthens GSK’s position in biomarker-driven cancer treatment. GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer
• Positive Sentiment: U.S. regulators approved GSK’s hepatitis B drug, offering eligible patients the possibility of stopping long-term treatment. The product could address a significant unmet need and create a new growth driver if adoption is strong. US FDA approves GSK's hepatitis B drug
• Positive Sentiment: GSK reported encouraging early data for experimental lung cancer therapy risvutatug rezetecan. The drug produced a 61% confirmed response rate at the 8 mg/kg dose in relapsed extensive-stage small-cell lung cancer, compared with 32% at the lower dose. The results improve the drug’s potential value, although the trial remains early-stage. GSK lung cancer drug shows 61% response rate in early global trial
• Positive Sentiment: Jefferies maintained a “buy” rating and set a 2,500-pence price target, citing the lung cancer data and potential upside for GSK. The endorsement reinforces investor confidence in the company’s pipeline. Jefferies backs GSK with 2,500p target
• Neutral Sentiment: Analysts have highlighted GSK’s newer medicines, expanded indications and pipeline as potential drivers of long-term sales growth, but much of that outlook depends on successful late-stage development, regulatory approvals and commercial execution.

About GSK

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.